Annual report pursuant to Section 13 and 15(d)

Commitment and Contingencies - Additional Information (Details)

Commitment and Contingencies - Additional Information (Details)			12 Months Ended
	Sep. 08, 2020 Debtinstrument	Jan. 21, 2020 Debtinstrument	Dec. 31, 2021 USD ($) $ / RNL	Nov. 18, 2015 USD ($)
Royalty-Linked Notes
Other Commitments [Line Items]
Debt instrument outstanding portion \| $ / RNL			0.04
Debt instrument maturity date			Dec. 31, 2045
Debt instrument aggregate potential payment capped rate			4,000
Royalty-Linked Notes \| Private Placement
Other Commitments [Line Items]
Number of debt instruments issued		2,579,400
Royalty-Linked Notes \| Rights Offering
Other Commitments [Line Items]
Number of debt instruments issued	11,000
Pfizer License Agreement \| Royalty-Linked Notes
Other Commitments [Line Items]
Debt instrument outstanding portion \| $ / RNL			0.04
Debt instrument maturity date			Dec. 31, 2045
Debt instrument price per unit \| $			$ 160.00
Debt instrument aggregate potential payment capped rate			4,000
Pfizer License Agreement \| Royalty-Linked Notes \| Private Placement
Other Commitments [Line Items]
Number of debt instruments issued		2,579,400
Pfizer License Agreement \| Royalty-Linked Notes \| Rights Offering
Other Commitments [Line Items]
Number of debt instruments issued	11,000
Pfizer License Agreement \| Minimum
Other Commitments [Line Items]
Potential future regulatory milestone and sales milestone payments upon achievement of net sales \| $				$ 250,000,000.0
Pfizer License Agreement \| Maximum
Other Commitments [Line Items]
Potential future regulatory milestone and sales milestone payments upon achievement of net sales \| $				$ 1,000,000,000.0